170 related articles for article (PubMed ID: 27613245)
1. The effect of increased lipoproteins levels on the disposition of vincristine in rat.
Khalil HA; Belal TS; El-Yazbi AF; Hamdy DA
Lipids Health Dis; 2016 Sep; 15(1):152. PubMed ID: 27613245
[TBL] [Abstract][Full Text] [Related]
2. Hyperlipidemia Alters the Pharmacokinetics of Posaconazole and Vincristine Upon Co-Administration in Rats.
Khalil HA; ElKhatib MAW; Belal TS; El-Yazbi AF; Hamdy DA
Drugs R D; 2017 Jun; 17(2):287-296. PubMed ID: 28299646
[TBL] [Abstract][Full Text] [Related]
3. The effect of hyperlipidemia on the pharmacokinetics, hepatic and pulmonary uptake of posaconazole in rat.
Khalil HA; Elnaggar MM; Belal TS; El-Yazbi AF; Hamdy DA
Eur J Pharm Sci; 2016 Aug; 91():190-5. PubMed ID: 27178487
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia.
Silverman JA; Reynolds L; Deitcher SR
J Clin Pharmacol; 2013 Nov; 53(11):1139-45. PubMed ID: 23907766
[TBL] [Abstract][Full Text] [Related]
5. Vincristine disposition in children with acute lymphoblastic leukemia.
de Graaf SS; Bloemhof H; Vendrig DE; Uges DR
Med Pediatr Oncol; 1995 Apr; 24(4):235-40. PubMed ID: 7700168
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma.
Yang F; Jiang M; Lu M; Hu P; Wang H; Jiang J
Front Pharmacol; 2018; 9():991. PubMed ID: 30210349
[No Abstract] [Full Text] [Related]
7. Pharmacokinetics of human immunodeficiency virus protease inhibitor, nelfinavir, in poloxamer 407-induced hyperlipidemic model rats.
Sugioka N; Haraya K; Maeda Y; Fukushima K; Takada K
Biol Pharm Bull; 2009 Feb; 32(2):269-75. PubMed ID: 19182388
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of liposomal-encapsulated and un-encapsulated vincristine after injection of liposomal vincristine sulfate in beagle dogs.
Zhong J; Mao W; Shi R; Jiang P; Wang Q; Zhu R; Wang T; Ma Y
Cancer Chemother Pharmacol; 2014 Mar; 73(3):459-66. PubMed ID: 24362508
[TBL] [Abstract][Full Text] [Related]
9. Decrease in motor performance in children with cancer is independent of the cumulative dose of vincristine.
Hartman A; van den Bos C; Stijnen T; Pieters R
Cancer; 2006 Mar; 106(6):1395-401. PubMed ID: 16453332
[TBL] [Abstract][Full Text] [Related]
10. Effect of hyperlipidemia on ketoconazole-midazolam drug-drug interaction in rat.
Hamdy DA; Brocks DR
J Pharm Sci; 2011 Nov; 100(11):4986-92. PubMed ID: 21698600
[TBL] [Abstract][Full Text] [Related]
11. The effect of increased lipoprotein levels on the pharmacokinetics of cyclosporine A in the laboratory rat.
Brocks DR; Ala S; Aliabadi HM
Biopharm Drug Dispos; 2006 Jan; 27(1):7-16. PubMed ID: 16278928
[TBL] [Abstract][Full Text] [Related]
12. Increasing the dosage of vincristine: a clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors.
Kellie SJ; Koopmans P; Earl J; Nath C; Roebuck D; Uges DR; De Graaf SS
Cancer; 2004 Jun; 100(12):2637-43. PubMed ID: 15197807
[TBL] [Abstract][Full Text] [Related]
13. [L-asparaginase-induced hyperlipidemia in a case of acute lymphoblastic leukemia].
Konya H; Tamura S; Miyazaki E; Inoue N; Okamoto T; Takemoto Y; Kohsaki M; Kanemaru A; Kakishita E
Rinsho Ketsueki; 1991 Mar; 32(3):250-4. PubMed ID: 2041167
[TBL] [Abstract][Full Text] [Related]
14. Vincristine pharmacokinetics after repetitive dosing in children.
Gidding CE; Meeuwsen-de Boer GJ; Koopmans P; Uges DR; Kamps WA; de Graaf SS
Cancer Chemother Pharmacol; 1999; 44(3):203-9. PubMed ID: 10453721
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: a surrogate marker of brain penetration.
Kellie SJ; Barbaric D; Koopmans P; Earl J; Carr DJ; de Graaf SS
Cancer; 2002 Mar; 94(6):1815-20. PubMed ID: 11920545
[TBL] [Abstract][Full Text] [Related]
16. Proactive therapeutic drug monitoring of vincristine in pediatric and adult cancer patients: current supporting evidence and future efforts.
Wu CY; Li GT; Chu CC; Guo HL; Fang WR; Li T; Wang YR; Xu J; Hu YH; Zhou L; Chen F
Arch Toxicol; 2023 Feb; 97(2):377-392. PubMed ID: 36418572
[TBL] [Abstract][Full Text] [Related]
17. N1-guanyl-1,7-diaminoheptane enhances the chemosensitivity of acute lymphoblastic leukemia cells to vincristine through inhibition of eif5a-2 activation.
Liu Y; Xue F; Zhang Y; Lei P; Wang Z; Zhu Z; Sun K
Anticancer Drugs; 2017 Nov; 28(10):1097-1105. PubMed ID: 28885268
[TBL] [Abstract][Full Text] [Related]
18. Decrease in brain distribution of fluvoxamine in experimental hyperlipidemic rats.
Fukushima K; Kobuchi S; Shibata M; Takada K; Sugioka N
J Pharm Pharm Sci; 2011; 14(3):414-24. PubMed ID: 22202224
[TBL] [Abstract][Full Text] [Related]
19. [Transdermal and lymph targeting transfersomes of vincristine].
Lu Y; Hou SX; Zhang LK; Li Y; He JY; Guo DD
Yao Xue Xue Bao; 2007 Oct; 42(10):1097-101. PubMed ID: 18229621
[TBL] [Abstract][Full Text] [Related]
20. Relationship between tumor cell density and drug concentration and the cytotoxic effects of doxorubicin or vincristine: mechanism of inoculum effects.
Kobayashi H; Takemura Y; Ohnuma T
Cancer Chemother Pharmacol; 1992; 31(1):6-10. PubMed ID: 1458560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
